Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This cross-sectional study asked how pulmonary tuberculosis alters the gut microbiome and fecal metabolites. It combined 16S rRNA gene sequencing of the V3-V4 regions with untargeted gas chromatography-mass spectrometry. Researchers compared fecal microbial communities, short-chain fatty acids, and metabolomic profiles between patients and controls. Random forest models tested whether these features could discriminate tuberculosis.
Who was studied?
The study enrolled 83 patients with untreated active pulmonary tuberculosis and 52 age- and sex-matched healthy controls in China. All patients were newly diagnosed before starting chemotherapy. Infection status was confirmed by interferon-gamma release testing. Fresh fecal and blood samples were collected from each adult participant for sequencing and biochemical analysis.
What were the most important findings?
Tuberculosis patients had significantly lower gut diversity, with fewer observed species (206 versus 254) and reduced Chao1, ACE, Shannon, and Simpson indices. Fecal short-chain fatty acids, including butyric, isobutyric, 2-methylbutyric, and valeric acids, dropped markedly. Bacteroidetes rose to 44.92% in patients versus 27.82% in controls, while several butyrate-linked genera declined. Serum total cholesterol, LDL, and VLDL were significantly lower in patients. A five-metabolite random forest model separated groups with an area under the curve of 0.998.
What are the greatest implications of this study?
The results link tuberculosis to reduced gut diversity, lost short-chain fatty acid production, and shifted metabolites. These features may serve as noninvasive diagnostic markers, useful for patients unable to produce sputum. The design is observational and cannot prove the dysbiosis drives disease. Nutritional support and prebiotics emerge as possible adjuncts worth testing in tuberculosis care.